Microarray Analysis of Scalp Biopsies After Minoxidil Treatment
|Study Design:||Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Basic Science
|Official Title:||Microarray Analysis of Scalp Biopsies in Subjects With Androgenetic Alopecia Before and After the Use of Topical Minoxidil|
- Analysis of change in gene expression before and after topical minoxidil application [ Time Frame: at baseline and after 8 weeks of treatment ]
- Differences ing ene expression in two different regions of the scalp, frontal and vertex. [ Time Frame: Baseline and after 8 weeks of treatment ]
|Study Start Date:||April 2011|
|Study Completion Date:||April 2012|
|Primary Completion Date:||April 2012 (Final data collection date for primary outcome measure)|
Patients received Minoxidil (same strength as sold over the counter) twice a day for 8 weeks.
Over the counter Rogaine, twice a day for 8 weeks
Other Name: Rogaine
Placebo Comparator: Placebo
The most common type of hair loss is androgenetic alopecia (AGA), also known as male pattern balding, or hereditary thinning. In AGA, there is a gradual transformation of large terminal hair follicles to miniaturized ones under the influence of circulating androgens that produce smaller and finer hairs with a shorter anagen cycle. This transformation, which can be seen as early as the prepubescent years, occurs only in certain regions of the scalp: the frontal hairline, top and vertex scalp. The temporo-occipital region is largely unaffected even in those with extensive balding.
The first drug to be approved for the FDA for the treatment of AGA was topical minoxidil solution (TMS). Despite its successful use, the mechanism of action of TMS is not well understood. Minoxidil is a potent vasodilator and potassium channel opener, but its mechanism of action in promoting hair regrowth appears to be independent of its vasodilation properties. Improved knowledge of the changes in gene expression associated with AGA before and after treatment with TMS and compared to placebo may lead to a greater understanding of the underlying mechanisms of action of TMS. Furthermore, there is potential for identification of those patients who would best respond to or benefit from treatment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01309191
|United States, Ohio|
|Skin Study Center, UH Case Medical Center|
|Cleveland, Ohio, United States, 44106|
|Principal Investigator:||Pratima Karnik, Ph.D.||UH Case Medical Center|